Clinical Trial

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-02.
Trial Details
NCT Number NCT07520006
Lead Sponsor Nurix Therapeutics, Inc.
Conditions B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Enrollment 150 participants
Start Date 2026-05
Primary Completion 2033-05 (estimated)
Study Completion 2033-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-13